MIRA PHARMACEUTICALS, INC. MIRA
Pharmaceuticals, Inc. (NASDAQ: MIRA, the "Company", "we", "us") is a clinical-stage pharmaceutical
development company advancing a pipeline of novel oral therapeutics targeting neurologic, neuropsychiatric, metabolic, and addiction-related
disorders. The Company holds exclusive rights in the United States, Canada, and Mexico to Ketamir-2, MIRA-55, and SKNY-1, three drug
candidates designed to address significant unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders,
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D | $1.7M | $3.3M | $1.6M | $2.4M | — |
| SG&A | $8.8M | $4.7M | $6.5M | $3.0M | — |
| Total operating expenses | $10.5M | $8.0M | $8.5M | $7.0M | — |
| Interest expense | $98.9K | $165.7K | $3.5M | $10.2K | — |
| Net income | -$10.4M | -$7.9M | -$12.0M | -$7.1M | — |
| EPS, basic | -1.35 | -0.51 | -0.85 | -0.40 | — |
| EPS, diluted | -1.35 | -0.51 | -0.85 | -0.40 | — |
| Shares, diluted (wtd. avg.) | 23.7M | 15.4M | 13.9M | 17.6M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $6.3M | $2.8M | — | — | — |
| Short-term investments | $4.7M | — | — | — | — |
| Total current assets | $11.1M | $2.9M | $4.9M | $494.4K | — |
| Total assets | $11.1M | $2.9M | $4.9M | $858.1K | — |
| Accounts payable | $129.2K | $723.3K | $538.6K | $811.7K | — |
| Total current liabilities | $702.1K | $723.3K | $558.1K | $1.4M | — |
| Total liabilities | $702.1K | $723.3K | $558.1K | $1.5M | — |
| Retained earnings | -$39.6M | -$29.1M | -$21.3M | -$9.3M | — |
| Total equity | $10.4M | $2.2M | $4.4M | -$596.2K | $2.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$4.7M | -$5.6M | -$4.5M | -$5.6M | — |
| Stock-based compensation | $6.3M | $1.9M | $2.6M | $1.3M | — |
| Financing cash flow | $8.2M | $3.8M | $8.8M | $3.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014001.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Net income | — | -$7.1M | -$12.0M | -$7.9M | -$10.4M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |